Last updated on January 2015

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Restless Leg Syndrome
  • Age: Between 18 - 80 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Outpatients with a diagnosis of primary restless leg syndrome using the International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria
  • RLS symptoms ≥ 15 nights of the month prior to study enrollment and for ≥ 4 of 7 consecutive nights in the week prior to study enrollment (if untreated)
  • Age 18 years to 80 years
  • International Restless Legs Scale (IRLS) Total severity score of ≥ 15 (moderate to severe severity)
  • Had significant sleep disturbance on item 4 of IRLS
  • Women of child-bearing potential must use a reliable method of contraception
  • Informed consent. Subject must be willing and able to complete all study procedures.

Exclusion Criteria:

  • Any illness that in the investigator's opinion preclude participation in this study
  • Subjects with non-RLS-related sleep disorders (e.g., sleep apnea)
  • Subjects with neurological diseases or movement disorders other than RLS (e.g., diabetic neuropathy, Parkinson's disease, multiple sclerosis, dyskinesias, and dystonias)
  • Pregnancy or lactation
  • Concurrent participation in another clinical study
  • Dementia or other psychiatric illness that prevents the patient from giving informed consent (Mini-Mental State Examination scores less than 27)
  • Legal incapacity or limited legal capacity
  • History of RLS symptom augmentation or early-morning rebound with previous dopamine-agonist treatment
  • Clinically significant abnormalities in renal function
  • Presence of severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease
  • Concomitant treatment with drugs known to affect sleep/wake, RLS or periodic limb movements, including antidepressants. Subjects receiving treatment for RLS at screening will be required to discontinue and wash out for a minimum of 5 half-lives
  • Body mass index greater than 34 kg/m2

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.